Geron (GERN) Q2 Revenue Jumps 5,477%
(NASDAQ:GERN), a biotechnology company focused on therapies for blood disorders, released its second quarter 2025 results on August 6, 2025. The headline news was a sharp acceleration in RYTELO revenues and better-than-expected GAAP bottom-line results. The company reported GAAP revenue of $49.0 million, ahead of the $47.28 million GAAP analyst forecast, and GAAP earnings per share (EPS) of $0.02, which surpassed the consensus GAAP estimate of $(0.03). Commercial momentum for RYTELO, Geron's core medicine for lower-risk myelodysplastic syndromes (MDS), improved after a slow Q1 2025. The quarter showed progress in demand growth, with RYTELO demand increasing 17% quarter-over-quarter, commercial reach, and research pipeline milestones, making it a standout period for the company.
Source: Analyst estimates for the quarter provided by FactSet.
Geron develops and commercializes telomerase inhibitor therapies for blood cancers and blood disorders. Its lead product, RYTELO, is a medicine for transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes (MDS). The company's main focus is successfully launching and establishing RYTELO as a standard therapy in the U.S, which began following its approval in June 2024.
Source Fool.com
Geron Corp. Stock
With 8 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 4 € there is potential for a 260.69% increase which would mean more than doubling the current price of 1.11 € for Geron Corp..
